Cargando…

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

In this analysis we describe the effectiveness of first-line ibrutinib in 747 patients with chronic lymphocytic leukemia (CLL) and TP53 aberrations in a nationwide study with a 100% capture of patients who received the study drug. Median age was 71 years (range 32–95). An estimated treatment persist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigolin, Gian Matteo, Olimpieri, Pier Paolo, Summa, Valentina, Celant, Simone, Scarfò, Lydia, Tognolo, Lucia, Ballardini, Maria Pia, Urso, Antonio, Sessa, Mariarosaria, Gambara, Silvia, Cura, Francesca, Fortini, Monica, Ghia, Paolo, Cuneo, Antonio, Russo, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307816/ https://www.ncbi.nlm.nih.gov/pubmed/37380630 http://dx.doi.org/10.1038/s41408-023-00865-z

Ejemplares similares

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
por: Urso, Antonio, et al.
Publicado: (2023)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
por: Sessa, Mariarosaria, et al.
Publicado: (2020)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
por: Breccia, Massimo, et al.
Publicado: (2020)

Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
por: Russo, Pierluigi, et al.
Publicado: (2022)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
por: Rigolin, Gian Matteo, et al.
Publicado: (2017)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Trabectedin use in soft‐tissue sarcoma patients in a real‐world setting: Data from an Italian national drug‐access registry
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
por: Marchetti, Monia, et al.
Publicado: (2022)

COVID-19 prophylaxis: half-full or half-empty glass?
por: Scarfò, Lydia, et al.
Publicado: (2023)

Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report
por: Panareo, Stefano, et al.
Publicado: (2020)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
por: Innocenti, Idanna, et al.
Publicado: (2022)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
por: Torti, Carlo, et al.
Publicado: (2023)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS
por: Ghia, Paolo, et al.
Publicado: (2023)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
por: Siddiqui, Maria Tariq, et al.
Publicado: (2021)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
por: Puzzolo, Maria Cristina, et al.
Publicado: (2021)

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
por: Woyach, Jennifer A., et al.
Publicado: (2023)

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
por: Allan, John N., et al.
Publicado: (2021)

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
por: Woyach, Jennifer A., et al.
Publicado: (2023)

Tabhu: tools for antibody humanization
por: Olimpieri, Pier Paolo, et al.
Publicado: (2015)

Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis
por: Kratz, Christian P., et al.
Publicado: (2021)

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
por: Brown, Jennifer R., et al.
Publicado: (2018)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n94j6b7gu4oqcfmmcnird5btal